CymaBay Therapeutics, Inc. (CBAY) |
32.48 0 (0%) 03-21 16:00 |
Open: | |
High: | 32.48 |
Low: | 32.48 |
Volume: | 0 |
Market Cap: | 3,728(M) |
PE Ratio: | -32.81 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 37.95 |
Resistance 1: | 32.49 |
Pivot price: | 32.42 |
Support 1: | 32.27 |
Support 2: | 32.14 |
52w High: | 32.5 |
52w Low: | 7.2609 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
EPS | -101000000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -74.00 |
Return on Assets (ttm) | 557.9 |
Return on Equity (ttm) | -22.0 |
Fri, 22 Mar 2024
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul - TipRanks.com - TipRanks
Mon, 11 Mar 2024
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain - Yahoo Finance
Thu, 29 Feb 2024
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk - TipRanks.com - TipRanks
Wed, 28 Feb 2024
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fri, 16 Feb 2024
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Mon, 12 Feb 2024
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary ... - PR Newswire
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |